Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth

351 views

Published on

IntroductionThe UK prescription pharmaceutical market was valued at $28.4 billion in 2009. Key growth drivers include growing use of chronic high-value innovative treatments driven by a rising elderly population, high public healthcare expenditure as proportion of total healthcare expenditure, relatively light pricing controls through the PPRS, and speedy domestic drug approvals.Scope*Overview of the UK's socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property position*Assesses the size of the UK's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies*Examines the UK's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion*Quantifies the UK's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.HighlightsThe UK pharmaceutical industry has to some extent been cushioned from the effects of the recession. However, the NHS now faces cuts and with price cuts to be implemented in Southern Europe further stimulating the parallel exportation of drugs out of these markets, branded drug sales in the UK market will certainly be impacted.The UK's Department of Health is considering imposing mandatory generic substitution at the pharmacist level, as part of the renegotiated PPRS which came into effect in 2009. Mandatory substitution should boost generics volume uptake in the UK, but the extent of the increase is likely to be limited, given the widespread use of generics in the UK.The UK has a strong track record for drug development. However, Roche and Novartis have threatened to pull out of the UK due to ongoing debates over drug pricing, expensive and bureaucratic clinical trials, and recent non-approval decisions by NICE. Also, a number of key players are downsizing their UK operations in an effort to reduce costs.Reasons to Purchase*Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.*Quantify the size and growth of the prescription pharmaceutical market in the UK, analyzing key therapy areas, brands and companies.*Assess drivers and resistors of generic and biosimilars uptake in the UK as well as the level of erosion brands can expect to face post patent expiry.

  • Be the first to comment

  • Be the first to like this

UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!UK Pharmaceutical Market Overview - Pricing and reimbursementchallenges dampen future growthPublished on June 2010 Report SummaryIntroductionThe UK prescription pharmaceutical market was valued at $28.4 billion in 2009. Key growth drivers include growing use of chronichigh-value innovative treatments driven by a rising elderly population, high public healthcare expenditure as proportion of totalhealthcare expenditure, relatively light pricing controls through the PPRS, and speedy domestic drug approvals.Scope*Overview of the UKs socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement andintellectual property position*Assesses the size of the UKs pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies*Examines the UKs generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree ofbrand erosion*Quantifies the UKs R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics anddomestic M&A analysis.HighlightsThe UK pharmaceutical industry has to some extent been cushioned from the effects of the recession. However, the NHS now facescuts and with price cuts to be implemented in Southern Europe further stimulating the parallel exportation of drugs out of thesemarkets, branded drug sales in the UK market will certainly be impacted.The UKs Department of Health is considering imposing mandatory generic substitution at the pharmacist level, as part of therenegotiated PPRS which came into effect in 2009. Mandatory substitution should boost generics volume uptake in the UK, but theextent of the increase is likely to be limited, given the widespread use of generics in the UK.The UK has a strong track record for drug development. However, Roche and Novartis have threatened to pull out of the UK due toongoing debates over drug pricing, expensive and bureaucratic clinical trials, and recent non-approval decisions by NICE. Also, anumber of key players are downsizing their UK operations in an effort to reduce costs.Reasons to Purchase*Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 1/12
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!*Quantify the size and growth of the prescription pharmaceutical market in the UK, analyzing key therapy areas, brands andcompanies.*Assess drivers and resistors of generic and biosimilars uptake in the UK as well as the level of erosion brands can expect to facepost patent expiry. Table of ContentABOUT DATAMONITOR HEALTHCARE 2About the Healthcare Strategic Analysis Team 2Country specific reports: 2Global issue reports: 21. Executive Summary 3Strategic scoping and focus 3Key findings - UK healthcare drivers and resistors 4Socio-demographic and economic analysis 8UK socio-demographic trends 8UK socio-economic trends 8Healthcare system and drug regulatory analysis 10UK healthcare expenditure 10UK healthcare system overview 11UK regulatory issues 11UK pricing and reimbursement issues 11Prescription pharmaceutical sales analysis 13UK pharmaceutical market size 13UK leading therapy areas 13UK leading prescription pharmaceutical brands 13UK pharmaceutical companies 13Drug expiry analysis 15UK generics market 15UK brand erosion post patent expiry 15UK biosimilars market 15Pharmaceutical industry infrastructure analysis 17UK pharmaceutical industry infrastructure overview 17UK R&D infrastructure trends 17UK manufacturing infrastructure trends 18Related reports 20Upcoming related reports 20Table of Contents 212. Socio-demographic and economic analysis 22Key findings 22UK socio-demographic trends 22UK socio-economic trends 22Demographic trends in the UK 23UK population growth rate expected to slow 24UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 2/12
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Birth rate in UK is declining 26Proportion of elderly people in the UK expected to rise and then level off 27Life expectancy will continue to increase in the UK and across other markets 28Disease burden in the UK 29Ischemic heart disease is the leading cause of death in the UK 29Non-communicable diseases are the main cause of overall disease burden in the UK 31Communicable diseases are a relatively uncommon cause of death in the UK, but healthcare-associated infections are on the rise 32Political climate in the UK 33The recent general election has resulted in a change of ruling political party and the formation of a coalition government 33UK economy still vulnerable after recession 34Pharma has historically been relatively well insulated from the recession, but the NHS could face cuts 36The UK has high standards of living, but there are income inequalities 37Business environment in the UK 37UK corporate tax rate one of the lowest in the EU 37Unemployment rate is high 383. Healthcare system and drug regulatory analysis 39Key findings 39UK healthcare expenditure 39UK healthcare system 39UK regulatory issues 39UK pricing and reimbursement issues 40Healthcare expenditure - UK lags behind most developed nations 41Healthcare system in the UK 43NHS is the main healthcare provider in the UK 43A number of stakeholders exist within the NHS 44Investment in the NHS has risen substantially over the last decade, but cuts loom 46UK is lagging behind other countries in health outcomes 46Private healthcare provision is supplementary to the NHS 47Primary versus hospital care - the number of hospital beds is falling in the UK as community care becomes more prominent 48Healthcare system reform in the UK 48Regulatory issues in the UK 50Drug approval and regulatory processes 50MHRA is the national body in charge of regulating medicines 50Cost of regulatory filings varies according to type of authorization procedure used 51UKs MHRA boasts short approval times 52The application process in the UK is straightforward 53UK license holders must report adverse drug reactions to EudraVigilance 54New initiatives aim to reduce regulatory burdens on Pharma 54The EU centralized procedure is convenient but expensive 54Decentralized procedure introduced to address disputes in mutual recognition procedure 55Country order of launch - brands tend to launch early in the UK 55Intellectual property environment UK court determines validity of patents in the UK 56High number of patent litigations and expensive fees but litigation times are short 56Supplementary protection certificates give extra protection 57Data exclusivity issues in the UK - the 8+2+1 rule 57Pediatric SPC extension provides additional market exclusivity period 58Drug counterfeiting - UK is becoming an easy target for counterfeiters 58Drug importation in the UK companies wishing to import or export medicines must have licenses 59UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 3/12
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Although the UK is generally a target country for parallel trade a recent surge in parallel exports has led to shortages of medicines 60Pricing and reimbursement in the UK 62Pricing issues in the UK 64PPRS is a light form of pricing regulation 642009 PPRS introduced flexible pricing to reward innovation 66Value-based pricing in the future 66UK drug prices among lowest in Western markets as a result of weak pound 67Discounts obtained by hospitals, PCTs and pharmacies add further complexity to determining UK drug prices 68Reimbursement issues in the UK 68NICE is the key reimbursement body in the UK 68SMC is NICEs equivalent in Scotland 69Cost-effectiveness analysis forms the basis of NICEs appraisal 69NICE appraises only a subset of drugs 71NICEs review process - thorough but lengthy 72Patient empowerment can have an impact on NICE reviews 73Time delays caused by NICE are a significant issue 74NICE has issued a number of controversial decisions and negative guidance over the past few years 74Lack of transparency and over-reliance on QALY draws criticism from pharma industry 75NICEs appraisal process prompted parliamentary review 76Risk-sharing schemes are becoming the norm for expensive drugs 77End-of-life guidance does not guarantee NICE approval 79Better access to drugs on the horizon in the UK 80Will the new cancer drug fund improve access to cancer treatments in the UK 81Other pricing and reimbursement issues in the UK 81Prescription charges do not have a significant impact on which drug is dispensed 81Top-up payments have been introduced recently but used mostly for drugs not approved by NICE 814. Prescription pharmaceutical sales analysis 82Key findings 82Pharmaceutical market size in the UK 83Leading therapy areas in the UK 85Central nervous system drugs hold the largest share of the UK market value 87Oncology drugs exhibited the strongest sales during 2005-09 88Immunology and inflammation drugs showed the fastest sales growth between 2008 and 2009 88Gastroenterology and cardiovascular drugs saw declining sales 88Leading prescription pharmaceutical brands in the UK 90Leading brand Seretide may face competition from faster-growing Symbicort 91Lipitor has begun to suffer from sales erosion from other generic statins 91Enbrels solid growth is attributed to its superior efficacy and having secured approval for multiple indications 91Leading pharmaceutical companies in the UK prescription pharmaceutical market 94The leading international companies struggle to maintain growth momentum 95The leading domestic companies experience impressive growth 98GlaxoSmithKline 99AstraZeneca 100Shire 1005. Drug expiry analysis 101Key findings 101UK generics market 101UK brand erosion post patent expiry 101UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 4/12
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!UK biosimilars market 101UK generics market dynamics 103UK generics volume uptake 104UK generics value uptake 105UK generics market size 106Drivers and resistors in the UK generics market 107The proportion of prescribed and dispensed generic drugs has been steadily rising in the UK 108The government is looking to impose mandatory generic substitution to further drive generic uptake 109Improved efficiency in generic pricing across PCTs could significantly cut drug costs 110Savings achievable through increased generic statin use have made them a target for cost-cutting initiatives 110Large price differential between brands and generics is indicative of a commodity generics market in the UK 111Key generics players in the UK market 113Opportunities for the generics industry 114Small molecule brand erosion in the UK 116Overview of drugs analyzed 116Mean level of brand erosion in the UK 117Brand erosion in the UK retail and hospital setting 118Brand erosion by therapy area in the UK 120Brand erosion by drug formulation in the UK 122UK biosimilars market dynamics 124Drivers and resistors to biosimilar uptake in the UK - hospital purchasing decisions pivotal to driving biosimilar uptake 124Key players in the UK biosimilars market 125Biosimilar epoetin 125Epoetin volume and value market share 126Branded epoetin prices in the UK market post biosimilar entry 128Biosimilar epoetin market share 129Biosimilar filgrastim 130Filgrastim volume and value market share 130Branded filgrastim prices in the UK market post biosimilar entry 132Biosimilar filgrastim market share 134Biosimilar somatropin 135Somatropin volume and value market share 136New and future biosimilar launches 138Opportunities for the biosimilars industry 139Branded monoclonal antibody therapies could soon face biosimilar incursion 142Biosimilars in development internationally 1436. Pharmaceutical industry infrastructure analysis 145Key findings 145UK pharmaceutical industry infrastructure overview 145UK R&D infrastructure trends 145UK manufacturing infrastructure trends 145UK pharmaceutical industry infrastructure overview 147R&D and manufacturing strategies in the UK 147R&D operations downsized to produce more focused pipeline offering higher returns 148Manufacturers reduce investment in UK facilities and look to outsourcing 149Key company infrastructure in the UK 149Pfizer 150Pfizers acquisition and integration of Wyeth has resulted in the closure of two R&D sites 153UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 5/12
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Pfizer phases out manufacturing in the UK 153Pfizer enhances its biotech capabilities through M&A activity 155GlaxoSmithKline 156GlaxoSmithKline restructures to focus on rare diseases, downsizing R&D in the UK 158Two manufacturing plants to shut due to lower demand as a result of generic competition 159Berkshire Hathaway buys a small stake in GlaxoSmithKline 161Sanofi-Aventis 162Sanofi-Aventis restructures, cutting R&D spend in favor of R&D partnership agreements 164Lower demand for maturing drugs leads to closure of a UK manufacturing plant 164Sanofi-Aventiss acquisition of Acambis expands its vaccines offering 166AstraZeneca 167AstraZeneca to implement heavy cuts in R&D workforce 169Manufacturing capabilities replaced by outsourcing 169Merck & Co. 171Roche 175Roches strengthens its pipeline with promising early-stage compounds 179Johnson & Johnson 180DePuy strengthens its hip implants offering through the acquisition of Finsbury Orthopaedics 182Eli Lilly 184Novartis 188UK manufacturing site helped Novartis reach record sales in 2009 190Latest restructuring plan has created a leaner operating environment 191Boehringer Ingelheim 1927. Bibliography 196Executive Summary 196Publications and online articles 196Datamonitor reports and products 196Socio-demographic and Economic analysis 196Publications and online articles 196Datamonitor reports and products 198Healthcare system & drug regulation 198Publications and online articles 198Datamonitor reports and products 204Pharmaceutical sales analysis 205Publications and online articles 205Datamonitor reports and products 205Drug expiry analysis 205Publications and online articles 205Datamonitor reports and products 208Industry infrastructure analysis 209Publications and online articles 209Datamonitor reports and products 211APPENDIX 212Exchange rates 212UK brand erosion - additional data and analysis 213UK brand erosion - methodology 215UK brand erosion - therapy area classification 217About Datamonitor 218UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 6/12
  7. 7. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!About Datamonitor Healthcare 218Datamonitor consulting 218Disclaimer 220List of TablesTable 1: UK - changes in the key value drivers of the UK pharmaceutical market, 2005-09 6Table 2: UK - demographic indicators, 2005 and 2010 8Table 3: UK - key economic indicators, 2005-2012 9Table 4: UK - healthcare expenditure indicators, 2006-09 10Table 5: UK - pricing and reimbursement tools, 2010 12Table 6: UK - sales and volume of the prescription pharmaceutical market ($ and IMS Standard Units), 2009 14Table 7: UK - key metrics for the generics and biosimilars market, 2010 16Table 8: UK - pharmaceutical industry metrics, 2007-09 17Table 9: UK - R&D and manufacturing infrastructure mean data for top 10 pharma companies in the UK, 2008-2010 19Table 10: UK - demographic indicators, 2005 and 2010 23Table 11: UK - top 10 causes of mortality, 2004 29Table 12: UK - disability-adjusted life years (DALY) rates compared to Australia, Japan, the BRIC nations, North America and otherkey European markets, 2004 31Table 13: UK - key economic indicators, 2005-2012 34Table 14: UK - healthcare expenditure indicators, 2006-09 42Table 15: UK - hospital bed and healthcare worker density, 2002 and 2007 48Table 16: UK - fees payable to Medicines and Healthcare products Regulatory Agency (MHRA). 2010 51Table 17: Order of launch for new molecules in the US, Japan, France, Germany, Italy, Spain, UK, Canada and Australia 55Table 18: UK - a range of pricing and reimbursement tools are used 62Table 19: UK - Pharmaceutical Price Regulation Scheme (PPRS) mandated price adjustments, 2009-2013 65Table 20: UK - comparison of ex-manufacturer prices in the UK with selected developed nations, 2004-08 67Table 21: UK - NICE has rejected a number of drugs on the basis of poor cost-effectiveness 75Table 22: UK - risk-sharing agreements companies entered into with NICE, 2009-2010 77Table 23: UK - sales and volume of the prescription pharmaceutical market ($ and IMS Standard Units), 2009 84Table 24: UK - pharmaceutical sales by therapy area ($m and %), 2005-09 86Table 25: UK - pharmaceutical volume by therapy area (SUm and %), 2005-09 87Table 26: UK - sales growth for top 20 pharmaceutical brands ($m and %), 2009 92Table 27: UK - volume growth for top 20 pharmaceutical brands (SUm and %), 2009 93Table 28: UK - sales growth for the leading international pharmaceutical companies ($ and %), 2009 96Table 29: UK - volume growth for the leading international pharmaceutical companies in the UK (SU and %), 2009 97Table 30: UK - sales growth for the leading UK-based pharmaceutical companies ($ and %), 2009 98Table 31: UK - volume growth for the leading UK-based pharmaceutical companies (SU and %), 2009 99Table 32: UK - key metrics for the generics and biosimilars market, 2010 102Table 33: UK - comparison of generic penetration versus other major pharmaceutical markets ($ billion and %), 2007-08 103Table 34: UK - leading generics companies, 2009 113Table 35: UK - brands exposed to generic competition, 2010-12 114Table 36: UK - key metrics for the biosimilars market, 2009 124Table 37: UK - leading biosimilar companies, 2009 125Table 38: Biosimilars approved and rejected in Europe by the European Medicines Agency (EMA) to May 2010 138Table 39: UK - sales (based on 2009 sales data) of biologics both expired and expected to come off-patent in 2010-15 141Table 40: UK - pharmaceutical industry metrics, 2007-09 147Table 41: UK - prescription sales growth for the top 10 pharmaceutical companies ($m and %), 2009 149Table 42: UK - Pfizers R&D and manufacturing infrastructure (post-merger with Wyeth), 2010 150Table 43: UK - Pfizers R&D and manufacturing infrastructure data (post-merger with Wyeth), 2010 151UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 7/12
  8. 8. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Table 44: UK - Pfizers UK-based M&A activity, 2008-2010 155Table 45: UK - GlaxoSmithKlines R&D and manufacturing infrastructure, 2010 156Table 46: UK - GlaxoSmithKlines R&D and manufacturing infrastructure data, 2010 157Table 47: UK - GlaxoSmithKlines UK-based M&A activity, 2008-2010 161Table 48: UK - Sanofi-Aventiss R&D and manufacturing infrastructure, 2010 162Table 49: UK - Sanofi-Aventiss R&D and manufacturing infrastructure data, 2010 163Table 50: UK - Sanofi-Aventiss UK-based M&A activity, 2008-2010 166Table 51: UK - AstraZenecas R&D and manufacturing infrastructure, 2010 167Table 52: UK - AstraZenecas R&D and manufacturing infrastructure data, 2010 168Table 53: UK - Merck & Cos R&D and manufacturing infrastructure (post acquisition of Schering-Plough), 2010 171Table 54: UK - Merck & Cos R&D and manufacturing infrastructure data (post acquisition of Schering-Plough), 2010 172Table 55: UK - Roches R&D and manufacturing infrastructure, 2010 175Table 56: UK - Roches R&D and manufacturing infrastructure data, 2010 176Table 57: UK - Roches UK-based M&A activity, 2008-2010 179Table 58: UK - Johnson & Johnsons R&D and manufacturing infrastructure, 2010 180Table 59: UK - Johnson & Johnsons R&D and manufacturing infrastructure data, 2010 181Table 60: UK - Johnson & Johnsons UK-based M&A activity, 2008-2010 183Table 61: UK - Eli Lillys R&D and manufacturing infrastructure, 2010 184Table 62: UK - Eli Lilly R&D and manufacturing infrastructure data, 2010 185Table 63: UK - Novartiss R&D and manufacturing infrastructure, 2010 188Table 64: UK - Novartiss R&D and manufacturing infrastructure data, 2010 189Table 65: UK - Boehringer Ingelheims R&D and manufacturing infrastructure, 2010 192Table 66: UK - Boehringer Ingelheims R&D and manufacturing infrastructure data, 2010 193Table 67: Currency exchange rates, 2010 212Table 68: ATC (anatomical therapeutic chemical) classification codes assigned to a given therapy area 217List of FiguresFigure 1: UK - key value drivers of the UK pharmaceutical market, 2009 4Figure 2: UK - drivers and resistors facing branded pharmaceutical companies 7Figure 3: UK - population and population growth rate, 1950-2050 24Figure 4: UK - population growth compared to the other seven major markets, Australia, Japan, the BRIC nations, North America andother key European markets, 1950-2050 25Figure 5: UK - birth rates per 1,000 individuals compared to the other seven major markets, Australia, Japan, the BRIC nations, NorthAmerica and other key European markets, 1950-2050 26Figure 6: UK - proportion of population over 65 years compared to the other seven major markets, Australia, Japan, the BRIC nations,North America and other key European markets, 1950-2050 27Figure 7: UK - life expectancy compared to the other seven major markets, Australia, Japan, the BRIC nations, North America andother key European markets,1950-2050 28Figure 8: UK - GDP per capita growth rate compared to, Australia, Japan, the BRIC nations, North America and other key Europeanmarkets, 2005-09 35Figure 9: Debt trap rankings for the UK, France, Germany, Italy, Spain, US, Canada, Australia and Japan, 2010 36Figure 10: Unemployment rates in the UK, France, Germany, Italy, Spain, US, Canada, Australia, Japan, Brazil, India, Russia andChina, 1990-2008 38Figure 11: UK - the proportion of GDP expenditure on healthcare is lower compared to most other developed nations, 2007 41Figure 12: UK - flow of money and accountability within the National Health Service (NHS) 44Figure 13: UK - primary care trusts (PCTs) are the key stakeholders within the National Health Service (NHS) 45Figure 14: UK - structure of the private healthcare system 47Figure 15: UK - four routes for obtaining market authorization in the UK 51Figure 16: UK - Medicines and Healthcare products Regulatory Agency (MHRA) application process 53UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 8/12
  9. 9. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Figure 17: EU - the 8+2+1 market exclusivity rule 57Figure 18: UK - a number of different bodies impact drug prescription and use 63Figure 19: UK - advantages and disadvantages of the Pharmaceutical Price Regulation Scheme (PPRS) for the UK pharmaceuticalindustry 66Figure 20: UK - NICEs topic selection process 71Figure 21: UK - NICEs review process 73Figure 22: UK - drivers and resistors of entering into risk-sharing agreements 78Figure 23: UK - three new schemes aim to improve access to drugs, 2010 80Figure 24: UK - relative sales and volume of the UK prescription pharmaceutical market (indexed against volume or value in 2005),2005-09 83Figure 25: UK - pharmaceutical sales by therapy area (%), 2005-09 85Figure 26: UK - sales growth for the leading pharmaceutical brands ($m and %), 2009 90Figure 27: UK - sales growth for leading pharmaceutical companies (%), 2005-09 94Figure 28: UK - comparison of generic volume uptake versus other major pharmaceutical markets (%), 2007-08 104Figure 29: UK - comparison of generic value uptake versus other major pharmaceutical markets (%), 2007-08 105Figure 30: UK - comparison of generics market size versus other pharmaceutical markets ($ billion), 2007-08 106Figure 31: UK - key factors influencing the UK generic industry, 2010 107Figure 32: England - generic prescribing and dispensing (%), 1998-2008 108Figure 33: UK - brand sales at risk of generic erosion ($m), 2010-12 115Figure 34: UK - mean erosion (by value and volume) of branded small molecules during the first 2 years of generic competition (%)117Figure 35: UK - mean erosion (by value and volume) of branded small molecules by prescribing setting during the first 2 years ofgeneric competition 119Figure 36: UK - mean erosion (by value and volume) of branded small molecules by therapy area during the first 2 years of genericcompetition 121Figure 37: UK - mean erosion (by value and volume) of branded small molecules by formulation during the first 2 years of genericcompetition 123Figure 38: UK - biosimilar versus branded epoetin alpha volume uptake (%), 2009 126Figure 39: UK - biosimilar versus branded epoetin alpha value uptake (%), 2009 127Figure 40: UK - unit price for Aranesp, NeoRecormon and Eprex, 2008-09 128Figure 41: UK - biosimilar epoetin market share by volume (%), 2008-09 129Figure 42: UK - biosimilar versus branded filgrastim volume uptake (%), 2008-09 130Figure 43: UK - biosimilar versus branded filgrastim value uptake (%), 2008-09 131Figure 44: UK - unit price for Neupogen and Granocyte ($/SU), 2008-09 132Figure 45: UK - unit price for Neulasta ($/SU), 2008-09 133Figure 46: UK - biosimilar versus branded filgrastim market share by volume (%), 2008-09 134Figure 47: UK - biosimilar versus branded somatropin volume uptake (%), 2006-09 136Figure 48: UK - biosimilar versus branded somatropin value uptake (%), 2006-09 137Figure 49: UK - sales (based on 2009 sales data) of biologics both expired and expected to come off-patent during 2010-15 140Figure 50: Drivers and resistors to biosimilar monoclonal antibody entry, 2010 143Figure 51: Key biosimilars in development internationally by product class, 2010 144Figure 52: Pharmas strategic responses to slowing sales and operating profit growth 148Figure 53: UK - Pfizers R&D presence (post-merger with Wyeth), 2010 152Figure 54: UK - Pfizers pharmaceutical operations (post-merger with Wyeth), 2010 154Figure 55: UK - GlaxoSmithKlines R&D and manufacturing presence, 2010 158Figure 56: UK - GlaxoSmithKlines pharmaceutical operations, 2010 160Figure 57: UK - Sanofi-Aventiss R&D presence, 2010 164Figure 58: UK - Sanofi-Aventiss pharmaceutical operations, 2010 165UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 9/12
  10. 10. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Figure 59: UK - AstraZenecas R&D and manufacturing presence, 2010 169Figure 60: UK - AstraZenecas pharmaceutical operations, 2010 170Figure 61: UK - Merck & Cos R&D and manufacturing presence (post acquisition of Schering-Plough), 2010 173Figure 62: UK - Merck & Cos pharmaceutical operations (post acquisition of Schering-Plough), 2010 174Figure 63: UK - Roches R&D presence, 2010 177Figure 64: UK - Roches pharmaceutical operations, 2010 178Figure 65: UK - Johnson & Johnsons pharmaceutical operations, 2010 182Figure 66: UK - Eli Lillys R&D and manufacturing presence, 2010 186Figure 67: UK - Eli Lillys pharmaceutical operations, 2010 187Figure 68: UK - Novartiss R&D presence, 2010 190Figure 69: UK - Novartiss pharmaceutical operations, 2010 191Figure 70: UK - Boehringer Ingelheims R&D and manufacturing presence, 2010 194Figure 71: UK - Boehringer Ingelheims pharmaceutical operations, 2010 195Figure 72: UK - sales erosion of branded small molecules during the first 2 years of generic competition 213Figure 73: UK - volume erosion of branded small molecules during the first 2 years of generic competition 214Figure 74: Drugs experiencing generic erosion between Q1 2006 and Q2 2007 215Figure 75: Erosion curves for each drug experiencing generic entry 216Figure 76: Mean erosion curve for drugs A, B, and C experiencing generic entry 217UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 10/12
  11. 11. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth Product Formats Please select the product formats and the quantity you require. 1 User License--USD 11 400.00 Quantity: _____ Corporate License--USD 28 500.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 11/12
  12. 12. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth (From Slideshare) Page 12/12

×